Would you buy the stocks of the company that is loaded in debt, entangled in legal battles and generating crores of loss
All that you need to know about the Turnaround story of Venus Remedies Ltd
Categories
pharmaceuticals
Marksans Pharma Limited Q2 FY23 Earnings Conference Call Insights
Key highlights from Marksans Pharma Limited (MARKSANS) Q2 FY23 Earnings Concall Q&A Highlights: [00:12:45] Madhav Shastri asked about the new acquisition made
Orchid Pharma Ltd Q2 FY23 Earnings Conference Call Insights
Key highlights from Orchid Pharma Ltd (ORCHPHARMA) Q2 FY23 Earnings Concall Q&A Highlights: [00:05:20] Rupesh Jain from Intelsense Capital asked about capacity
IOL Chemicals and Pharmaceuticals Limited Q2 FY23 Earnings Conference Call Insights
Key highlights from IOL Chemicals and Pharmaceuticals Limited (IOLCP) Q2 FY23 Earnings Concall Q&A Highlights: [00:12:26] Venkat of 3Sigma Financials asked about
Aarti Industries Ltd Q2 FY23 Earnings Conference Call Insights
Key highlights from Aarti Industries Ltd (AARTIIND) Q2 FY23 Earnings Concall Management Update: [00:03:50] AARTIIND said it is seeing slower demand for
Everything You Need to Know About Brooks Laboratories Limited(NSE:BROOKS)| Stock UP 30% in 2 Months
Brooks Laboratories Limited(NSE:BROOKS) has an industry presence of nearly two decades now, leading to established relationships with the customers as well as
Infographic : Brooks Labrotories (NSE : BROOKS) | Q4FY22 Results Released! | Revenue UP 94.55% YoY
Brooks Laboratories Ltd is a pharmaceutical contract manufacturing company. The company has manufacturing facilities in Baddi Himachal Pradesh and Vadodara Gujarat. Both
Infographic : Brooks Labrotories (NSE : BROOKS) | Q1 Results Released! | Revenue DOWN 23.21% YoY
Brooks Laboratories Ltd is a pharmaceutical contract manufacturing company. The company has manufacturing facilities in Baddi Himachal Pradesh and Vadodara Gujarat. Both
Infographic : Brooks Labrotories (NSE : BROOKS) | Q2 Results Released! | Revenue DOWN 15.74% YoY
Brooks Laboratories Ltd is a pharmaceutical contract manufacturing company. The company has manufacturing facilities in Baddi Himachal Pradesh and Vadodara Gujarat. Both
JB Chemicals & Pharmaceuticals Limited Q2 FY23 Earnings Conference Call Insights
Key highlights from JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) Q2 FY23 Earnings Concall Management Update: [00:06:28] JBCHEPHARM said that in domestic markets
Biocon Limited Q2 FY23 Earnings Conference Call Insights
Key highlights from Biocon Limited (BIOCON) Q2 FY23 Earnings Concall Q&A Highlights: [00:23:49] Prakash Agarwal of Axis Capital asked about the mezzanine
Aarti Industries Ltd (AARTIIND) Q2 FY23 Earnings Concall Transcript
Aarti Industries Ltd (NSE:AARTIIND) Q2 FY23 Earnings Concall dated Nov. 15, 2022 Corporate Participants: Rajendra V. Gogri -- Chairman and Managing Director
JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) Q2 FY23 Earnings Concall Transcript
JB Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Q2 FY23 Earnings Concall dated Nov. 14, 2022 Corporate Participants: Jason D'Souza -- Vice President of Investor Relations Nikhil Chopra -- Chief
Aurobindo Pharma Limited (AUROPHARMA) Q2 FY23 Earnings Concall Transcript
Aurobindo Pharma Limited (NSE: AUROPHARMA) Q2 FY23 Earnings Concall dated Nov. 13, 2022 Corporate Participants: Deepti Thakur -- Investor Relations Santhanam Subramanian -- Chief Financial Officer
Gufic Biosciences Limited (GUFICBIO) Q1 FY23 Earnings Concall
Gufic Biosciences Limited (NSE:GUFICBIO) Q2 FY23 Earnings Concall dated Nov.13, 2022 Corporate Participants: Ami Naresh Shah -- Company Secretary and Compliance Officer Avik Das -- Investor
Alkem Laboratories Ltd (ALKEM) Q2 FY23 Earnings Concall Transcript
Alkem Laboratories Ltd (NSE:ALKEM) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Amit Kumar Khandelia -- Assistant Vice President, Finance
Supriya Lifescience Ltd (SUPRIYA) Q2 FY23 Earnings Concall Transcript
Supriya Lifescience Ltd (NSE:SUPRIYA) Q2 FY23 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Rasika Sawant -- Investor Relation Partner Satish Wagh
NATCO Pharma Limited (NATCOPHARM) Q2 FY22 Earnings Concall Transcript
NATCO Pharma Limited (NSE:NATCOPHARM) Q2 FY22 Earnings Concall dated Nov. 11, 2022 Corporate Participants: Rajeev Nannapaneni -- Director and Chief Executive Officer Rajesh Chebiyam -- Executive
Sequent Scientific Limited Q2 FY23 Earnings Conference Call Insights
https://youtu.be/-5pgj3qU44c Key highlights from Sequent Scientific Limited (SEQUENT) Q2 FY23 Earnings Concall Q&A Highlights: [00:17:40] Rishab Jain asked about Tineta Pharma acquisition,
Dr Lal PathLabs Ltd Q2 FY23 Earnings Conference Call Insights
https://youtu.be/lAaNZKEvjOc Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY23 Earnings Concall Q&A Highlights: [00:16:43] Rahul Agarwal with Incred Capital enquired
Lupin Q2FY23 results out: Net profit rises more than 100%
Shares of Lupin gained as much as 8 percent in early trading on Thursday after the company returned to profitability during the